Marktbericht über die Behandlung von Leberfibrose im Nahen Osten und Afrika: Größe, Anteil und Trendsanalyse – Branchenüberblick und Prognose bis 2032

Middle East And Africa Liver Fibrosis Treatment Market

Marktgröße in Milliarden USD

CAGR : 12.30 %

USD 935.44 Million USD 2,354.75 Million 2024 2032

Prognosezeitraum	2025 –2032
Marktgröße (Basisjahr)	USD 935.44 Million
Marktgröße (Prognosejahr)	USD 2,354.75 Million
CAGR	12.30 %
Wichtige Marktteilnehmer	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Anfrage zur Freischaltung

Markt für die Behandlung von Leberfibrose im Nahen Osten und Afrika, nach Behandlungsart (Medikamente und Chirurgie/Therapie), Stadien (F2, F1, F3 und F4), Indikation (Nichtalkoholische Steatohepatitis (NASH), Hepatitis B & C-induzierte Fibrose, Alkoholische Lebererkrankung (ALD), Autoimmune Lebererkrankungen, genetische Störungen und andere), Geschlecht (Männlich und Weiblich), Endverbraucher (Krankenhäuser, Fachkliniken, Kliniken, Ambulanzen und Forschungszentren und andere), Vertriebskanal (Direktausschreibung und Einzelhandelsverkauf) – Branchentrends und Prognose bis 2032

Marktgröße für die Behandlung von Leberfibrose im Nahen Osten und Afrika

Der Markt für die Behandlung von Leberfibrose im Nahen Osten und Afrika wurde im Jahr 2024 auf 935,44 Millionen US-Dollar geschätzt und wird bis 2032 voraussichtlich 2.354,75 Millionen US-Dollar erreichen.
Im Prognosezeitraum von 2025 bis 2032 wird der Markt voraussichtlich mit einer jährlichen Wachstumsrate von 12,3 % wachsen, was vor allem auf das zunehmende Bewusstsein der Verbraucher für natürliche Gesundheitslösungen zurückzuführen ist.
Dieses Wachstum ist auf Faktoren wie die zunehmende Verbreitung von Lebererkrankungen zurückzuführen. Darüber hinaus führt die Erschwinglichkeit des Alkohols zu einem steigenden Alkoholkonsum.

Marktanalyse für die Behandlung von Leberfibrose im Nahen Osten und Afrika

Die steigende Zahl von Lebererkrankungen führt dazu, dass immer mehr Patienten wirksame Therapieoptionen benötigen, insbesondere bei Erkrankungen wie Hepatitis B und C. Faktoren wie steigender Alkoholkonsum, ungesunde Ernährungsgewohnheiten und die Zunahme von Fettleibigkeit haben dazu geführt, dass immer mehr Menschen mit diesen Lebererkrankungen diagnostiziert werden.
Mit fortschreitender Leberschädigung steigt das Risiko einer Leberfibrose. Dies stellt eine erhebliche Belastung für die Gesundheitssysteme dar, wirksame Behandlungsmöglichkeiten anzubieten. Diese steigende Nachfrage treibt die Entwicklung und Verfügbarkeit zielgerichteter Therapien voran und beflügelt das Marktwachstum, da Gesundheitsdienstleister nach innovativen Lösungen für die Behandlung dieser Erkrankung suchen.
Darüber hinaus hat das gestiegene Bewusstsein von Ärzten und der breiten Öffentlichkeit dazu geführt, dass mehr Menschen in früheren Stadien einer Lebererkrankung untersucht und diagnostiziert werden. Fortschritte in der Diagnosetechnik, einschließlich nicht-invasiver Bildgebung und Blutuntersuchungen, haben es ermöglicht, Leberfibrose früher im Krankheitsverlauf zu erkennen. Diese Früherkennung ermöglicht rechtzeitige Interventionen und fördert die Nachfrage nach innovativen Behandlungen, die Leberfibrose wirksam umkehren oder behandeln.

Laut einem NCBI-Artikel sind Lebererkrankungen beispielsweise im August 2023 für zwei Millionen Todesfälle pro Jahr und 4 % aller Todesfälle (1 von 25 Todesfällen weltweit) verantwortlich; etwa zwei Drittel aller leberbedingten Todesfälle betreffen Männer. Diese alarmierende Statistik unterstreicht den dringenden Bedarf an wirksamen Behandlungsmöglichkeiten und verdeutlicht die erhebliche Belastung der öffentlichen Gesundheit durch Lebererkrankungen. Dies motiviert Gesundheitssysteme und Pharmaunternehmen zusätzlich, die Entwicklung innovativer Therapien, die speziell auf Leberfibrose und ihre Ursachen abzielen, zu priorisieren.

Folglich sind Pharmaunternehmen und medizinische Forscher gezwungen, in die Entwicklung neuer Therapiemöglichkeiten zu investieren und so den Markt anzukurbeln, da die Beteiligten die steigende Zahl von Lebererkrankungen und die damit verbundenen Komplikationen bekämpfen wollen.

Berichtsumfang und Marktsegmentierung für die Behandlung von Leberfibrose im Nahen Osten und Afrika

Eigenschaften	Globaler Markt für Leberfibrosebehandlungen – Wichtige Markteinblicke
Abgedeckte Segmente	Nach Behandlungstyp Medikamente Chirurgie/Therapie Etappen F2 F1 F3 F4 Anzeige Nichtalkoholische Steatohepatitis (NASH) Hepatitis B und C-induzierte Fibrose Alkoholische Lebererkrankung (ALD) Autoimmunerkrankungen der Leber Genetische Störungen Sonstige Geschlecht Männlich Weiblich Endbenutzer Krankenhäuser Fachkliniken Kliniken Ambulanz- und Forschungszentren Sonstige Vertriebskanal Direkte Ausschreibung Einzelhandelsumsätze
Abgedeckte Länder	Nordamerika LAUS Kanada Mexiko Europa Deutschland Frankreich Vereinigtes Königreich Italien Spanien Schweiz Russland Belgien Niederlande Truthahn Polen Schweden Norwegen Dänemark Finnland Restliches Europa Asien-Pazifik China Japan Indien Südkorea Australien Singapur Thailand Indonesien Malaysia Taiwan Neuseeland Philippinen Vietnam Restlicher Asien-Pazifik-Raum Südamerika Brasilien Argentinien Restliches Südamerika Naher Osten und Afrika Südafrika Saudi-Arabien Vereinigte Arabische Emirate Ägypten Israel Kuwait Katar Oman Rest des Nahen Ostens und Afrikas
Wichtige Marktteilnehmer	F. Hoffmann-La Roche Ltd (Schweiz) Abbott (USA) La Renon Healthcare Pvt. Ltd. (Indien) GENFIT SA (Frankreich) Madrigal Pharmaceuticals (USA) Aligos Therapeutics (USA) Pfizer Inc. (USA) Enanta Pharmaceuticals, Inc. (USA) Bristol-Myers Squibb Company (USA) Vertex Pharmaceuticals Incorporated (USA) Takeda Pharmaceutical Company Limited (Japan) Hepion Pharmaceuticals (USA) Echosens (Frankreich) Galectin Therapeutics, Inc. (USA) Conatus Pharmaceuticals (USA) Tvardi Therapeutics (USA) Viking Therapeutics (USA) Calliditas Therapeutics AB (Schweden) Novomedix (USA) Galecto Biotech (Dänemark) Pilant Therapeutics, Inc. (USA) Sagimet Biosciences (USA) Gyre Therapeutics, Inc. (USA) Akero Therapeutics, Inc. (USA) CureVac SE (Deutschland) Novo Nordisk A/S (Dänemark) Ipsen Pharma (Frankreich) AdAlta Limited (Australien) Alentis Therapeutics AG (Schweiz) Gilead Sciences, Inc. (USA) AbbVie Inc. (USA) Merck and Co., Inc. (USA) Novartis AG (Schweiz) Intercept Pharmaceuticals, Inc. (USA)
Marktchancen	Neue Technologien und fortschrittliche Behandlungen im Management von Leberfibrose Fortschritte bei Pipeline-Produkten zur Behandlung von Leberfibrose Strategische Fusionen und Übernahmen unter den Hauptakteuren
Wertschöpfungsdaten-Infosets	Zusätzlich zu den Einblicken in Marktszenarien wie Marktwert, Wachstumsrate, Segmentierung, geografische Abdeckung und wichtige Akteure enthalten die von Data Bridge Market Research kuratierten Marktberichte auch Import-Export-Analysen, eine Übersicht über die Produktionskapazität, eine Analyse des Produktionsverbrauchs, eine Preistrendanalyse, ein Szenario des Klimawandels, eine Lieferkettenanalyse, eine Wertschöpfungskettenanalyse, eine Übersicht über Rohstoffe/Verbrauchsmaterialien, Kriterien für die Lieferantenauswahl, eine PESTLE-Analyse, eine Porter-Analyse und regulatorische Rahmenbedingungen.

Markttrends zur Behandlung von Leberfibrose im Nahen Osten und Afrika

„Steigende Prävalenz von Lebererkrankungen“

Die zunehmende Verbreitung von Lebererkrankungen stellt im Nahen Osten und in Afrika ein erhebliches Gesundheitsproblem dar und trägt erheblich zur weltweiten Belastung des Gesundheitswesens bei.
Faktoren wie übermäßiger Alkoholkonsum, steigende Fettleibigkeitsraten, Virushepatitis-Infektionen und ein ungesunder Lebensstil führen zu einem Anstieg von Erkrankungen wie Fettleber, Leberzirrhose und Leberkrebs.
Auch die zunehmende Zahl nichtalkoholischer Fettlebererkrankungen (NAFLD), insbesondere im Zusammenhang mit Diabetes und dem Metabolischen Syndrom, ist besorgniserregend. Infolgedessen steigt der Bedarf an Frühdiagnose, wirksamen Behandlungsmöglichkeiten und Initiativen im Bereich der öffentlichen Gesundheit. Dieser Trend dürfte Innovation und Wachstum im Markt für Leberbehandlungen vorantreiben.

Marktdynamik für die Behandlung von Leberfibrose im Nahen Osten und Afrika

Treiber

„Steigender Alkoholkonsum“

Der steigende Alkoholkonsum trägt erheblich zum Markt für Leberfibrosebehandlungen im Nahen Osten und Afrika bei, da er in direktem Zusammenhang mit der Häufigkeit von Lebererkrankungen, insbesondere der alkoholischen Lebererkrankung (ALD), steht.
Da immer mehr Menschen regelmäßig und in größeren Mengen Alkohol konsumieren, steigt das Risiko für die Entwicklung von Leberkomplikationen, einschließlich Leberfibrose und Leberzirrhose, erheblich.
Chronischer Alkoholismus führt zu Entzündungen, Fettansammlungen und schließlich zu Fibrose, da die Leber wiederholt geschädigt und repariert wird
Die zunehmende Verbreitung alkoholbedingter Lebererkrankungen führt zu einem dringenden Bedarf an wirksamen Behandlungs- und Managementstrategien, um Leberschäden zu mildern und die Behandlungsergebnisse der Patienten zu verbessern.

Zum Beispiel,

Im Oktober 2024 lag die Prävalenz des Alkoholkonsums laut einem Artikel des International Journal of Mental Health Systems zu Beginn der Studie bei 54,5 % und in der Folgestudie bei 47,7 %. Darüber hinaus gaben 12 % der Männer an, neu mit dem Trinken begonnen zu haben. Dieser hohe Alkoholkonsum führt zu einer erhöhten Inzidenz von Leberfibrose im Nahen Osten und in Afrika und könnte das Marktwachstum beeinträchtigen.
Laut STAT nehmen die alkoholbedingten Todesfälle im Juni 2024 zu, und Experten sind besonders besorgt über einen Anstieg bei jungen Menschen und Frauen. In den USA gab es zwischen 2019 und 2020 einen Anstieg der alkoholbedingten Todesfälle um 25,5 % – das entspricht 3 % aller Todesfälle. Die stärksten Anstiege alkoholbedingter Todesfälle gab es bei den 25- bis 34-Jährigen und den 35- bis 44-Jährigen, wobei die Todesfälle in beiden Gruppen um über 37 % zunahmen.
Darüber hinaus verschärft die zunehmende gesellschaftliche Akzeptanz und Normalisierung des Alkoholkonsums, insbesondere in der jüngeren Bevölkerung, das Problem zusätzlich und führt dazu, dass eine größere Anzahl von Personen einem Risiko für fibrotische Veränderungen der Leber ausgesetzt ist.
Dieser Trend fördert das Wachstum des Marktes für die Behandlung von Leberfibrose und unterstreicht die Bedeutung von Initiativen im Bereich der öffentlichen Gesundheit, die auf die Reduzierung des Alkoholkonsums und die Vorbeugung von Lebererkrankungen abzielen.

Gelegenheiten

„Neue Technologien und fortschrittliche Behandlungen im Management von Leberfibrose“

Neue Technologien wie Gentherapie, gezielte Molekulartherapien und biologische Wirkstoffe verändern die Behandlungslandschaft
Aktuelle Innovationen konzentrieren sich auf Medikamente, die gezielt auf die Entstehungswege der Fibrose abzielen, wie etwa FXR-Agonisten, TGF-β-Hemmer und entzündungshemmende Mittel. Darüber hinaus verbessern nicht-invasive Diagnoseverfahren wie die Elastographie die Früherkennung.
Diese Fortschritte ermöglichen effektivere, personalisierte Behandlungen für Erkrankungen wie NASH (nichtalkoholische Steatohepatitis) und Leberzirrhose und führen zu besseren Behandlungsergebnissen für die Patienten.

Im Februar 2024 erschien ein Artikel in Springer Nature. Der Artikel untersucht neue Ansätze zur Diagnose und Hemmung der Leberfibrogenese. Zu den Fortschritten zählen nicht-invasive Biomarker, Bildgebungstechnologien und Zelltherapien wie mesenchymale Stammzellen. Vielversprechende antifibrotische Medikamente wie Pirfenidon und Obeticholsäure sowie Innovationen im Tissue Engineering, der Nanotechnologie und mikrofluidischen Modellen zeigen Potenzial für personalisierte, präzise Behandlungen.
Ein Artikel des NCBI vom September 2021 hob hervor, dass sich neue Technologien in der Behandlung von Leberfibrose auf fortschrittliche Therapien konzentrieren, die auf molekulare Prozesse wie die Aktivierung hepatischer Sternzellen abzielen. Innovationen wie Gentherapie, Biologika, niedermolekulare Inhibitoren und nicht-invasive Diagnostik verbessern die Früherkennung und Behandlung. Stammzelltherapien und Tissue Engineering bieten ebenfalls vielversprechende Möglichkeiten, die Fibrose umzukehren und die Genesung zu verbessern.

Mit der kontinuierlichen Weiterentwicklung von Behandlungsstrategien und Diagnosetechnologien entwickeln sich die Therapien für Leberfibrose rasant
Diese Innovationen geben Anlass zur Hoffnung auf eine bessere Behandlung von Lebererkrankungen und stellen sicher, dass Patienten Zugang zu wirksameren, personalisierten Behandlungen mit weniger Nebenwirkungen haben, was letztlich zu einer Verbesserung der Gesundheitssituation im Nahen Osten und in Afrika führt.

Einschränkungen/Herausforderung

„ Begrenztes Bewusstsein für Lebererkrankungen“

Das mangelnde Bewusstsein für Lebererkrankungen erschwert eine frühzeitige Diagnose und angemessene Intervention. Viele Menschen sind sich der Risikofaktoren und Symptome von Lebererkrankungen nicht bewusst und führen vage Krankheitsanzeichen oft auf andere, weniger schwerwiegende Probleme zurück.
Dieser Mangel an Wissen führt dazu, dass Arztbesuche erst dann erfolgen, wenn die Krankheit fortgeschrittene Stadien erreicht hat, wie etwa eine Leberfibrose oder Leberzirrhose, bei denen die Behandlungsmöglichkeiten komplexer und weniger wirksam werden.
Folglich verringern Diagnosen im Spätstadium das Potenzial für erfolgreiche Behandlungsergebnisse und schränken das allgemeine Marktwachstum ein, da die Zahl der Patienten, die rechtzeitig behandelt werden, begrenzt ist.

Zum Beispiel,

Im April 2024 erklärte Lupin, dass Patienten erst dann von ihrem Zustand erfahren, wenn die Krankheit ein kritisches Stadium erreicht. Dies mache eine Neubewertung des Ansatzes zur Sensibilisierung, Erkennung und Behandlung der Lebergesundheit dringend erforderlich. Eine wesentliche Hürde im Lebergesundheitsmanagement liege jedoch im begrenzten Verständnis von Lebererkrankungen und den damit verbundenen Risikofaktoren.
Laut einer Studie mit 11.700 Erwachsenen (ab 18 Jahren) aus fünf nationalen Gesundheits- und Ernährungsstudien wussten im Juli 2021 fast 96 % der Erwachsenen mit NAFLD in den USA nichts von ihrer Lebererkrankung, insbesondere unter jungen Erwachsenen. Daher ist eine stärkere Sensibilisierung und Aufklärung über die Lebergesundheit entscheidend, um die Behandlungsergebnisse zu verbessern und einen proaktiveren Ansatz im Umgang mit Leberfibrose und der Markterweiterung zu fördern.
Im Januar 2021 berichtete Springer Nature, dass von den 825 Patienten, die in die Forschungsanalyse für die Studie „Lack of awareness of liver organ damage in patients with type 2 diabetes“ einbezogen wurden, 8,1 % (95% KI 5,1%-12,7%) der Patienten mit Steatose wussten, dass sie eine Lebererkrankung hatten. Darüber hinaus ist in einer landesweit repräsentativen Stichprobe von US-amerikanischen Erwachsenen mit Typ-2-Diabetes die Prävalenz einer fortgeschrittenen Leberfibrose hoch. Weniger als 20 % der Patienten mit fortgeschrittener Fibrose wissen, dass sie eine Lebererkrankung haben.
Mangelndes Bewusstsein beeinträchtigt potenzielle Behandlungsergebnisse für Patienten und hemmt das Marktwachstum, da weniger Menschen frühzeitig Gesundheitsdienste in Anspruch nehmen.
Daher ist eine stärkere Sensibilisierung und Aufklärung über die Gesundheit der Leber von entscheidender Bedeutung, um die Frühdiagnose zu verbessern, die Wirksamkeit der Behandlung zu steigern und letztlich einen robusteren Markt für Leberfibrose-Therapien zu fördern.

Marktumfang der Leberfibrosebehandlung im Nahen Osten und in Afrika

Der Markt ist nach Produkttyp, Behandlung, Herkunftsbasis, Anwendung, Verabreichungsweg, Kaufart, Altersgruppe, Geschlecht, Endbenutzer und Vertriebskanal segmentiert.

Segmentierung	Untersegmentierung
Nach Behandlungstyp	Behandlungstyp Medikamente Chirurgie/Therapie
Nach Etappen	Etappen F2 F1 F3 F4
Nach Indikation	Anzeige Nichtalkoholische Steatohepatitis (NASH) Hepatitis B und C-induzierte Fibrose Alkoholische Lebererkrankung (ALD) Autoimmunerkrankungen der Leber Genetische Störungen Andere.
Nach Endbenutzer	Endbenutzer Krankenhäuser Fachkliniken Kliniken Ambulanz- und Forschungszentren Sonstige
Nach Vertriebskanal	Vertriebskanal Direkte Ausschreibung Einzelhandelsumsätze

„Saudi-Arabien ist das dominierende Land auf dem Markt für die Behandlung von Leberfibrose“

Saudi-Arabien ist im Nahen Osten und Afrika führend auf dem Markt für Leberfibrosebehandlungen. Grund hierfür ist die hohe Prävalenz von Lebererkrankungen, insbesondere der nichtalkoholischen Fettlebererkrankung (NAFLD) und Hepatitis C, sowie ein starker Fokus auf die Modernisierung des Gesundheitswesens im Rahmen der Initiative „Vision 2030“.
Das Land verfügt über eine sich rasch entwickelnde Gesundheitsinfrastruktur mit erheblichen staatlichen Investitionen in spezialisierte Leberkliniken, fortschrittliche Diagnosetechnologien und nicht-invasive Behandlungsmethoden.
Umfangreiche Screening-Programme sowie eine stärkere Sensibilisierung und Aufklärung der Patienten haben die Früherkennungsraten erhöht und so die Nachfrage nach wirksamen Therapien gegen Leberfibrose weiter angekurbelt.
Die nationale Gesundheitsstrategie Saudi-Arabiens legt den Schwerpunkt auf die Bekämpfung chronischer Lebererkrankungen durch Vorsorge, Forschung und bessere Protokolle zur Krankheitsbehandlung.

„Saudi-Arabien wird voraussichtlich die höchste Wachstumsrate verzeichnen“

Saudi-Arabien dürfte aufgrund der Einführung hochmoderner Biomarker, der zunehmenden Verfügbarkeit innovativer antifibrotischer Therapien und der zunehmenden Beteiligung von Pharmaunternehmen aus dem Nahen Osten und Afrika das am schnellsten wachsende Land auf dem Markt sein.
Diese Faktoren machen Saudi-Arabien zum größten und am schnellsten wachsenden Markt für die Behandlung von Leberfibrose im Nahen Osten und Afrika und dienen als Modell für die regionale Transformation des Gesundheitswesens.

Marktanteil der Leberfibrosebehandlung im Nahen Osten und Afrika

Die Wettbewerbslandschaft des Marktes liefert detaillierte Informationen zu den einzelnen Wettbewerbern. Zu den Details gehören Unternehmensübersicht, Unternehmensfinanzen, Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Präsenz im Nahen Osten und Afrika, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben genannten Datenpunkte beziehen sich ausschließlich auf die Marktausrichtung der Unternehmen.

Die wichtigsten Marktführer auf dem Markt sind:

F. Hoffmann-La Roche Ltd (Schweiz)
Abbott (USA)
La Renon Healthcare Pvt. Ltd. (Indien)
GENFIT SA (Frankreich)
Madrigal Pharmaceuticals (USA)
Aligos Therapeutics (USA)
Pfizer Inc. (USA)
Enanta Pharmaceuticals, Inc. (USA)
Bristol-Myers Squibb Company (USA)
Vertex Pharmaceuticals Incorporated (USA)
Takeda Pharmaceutical Company Limited (Japan)
Hepion Pharmaceuticals (USA)
Echosens (Frankreich)
Galectin Therapeutics, Inc. (USA)
Conatus Pharmaceuticals (USA)
Tvardi Therapeutics (USA)
Viking Therapeutics (USA)
Calliditas Therapeutics AB (Schweden)
Novomedix (USA)
Galecto Biotech (Dänemark)
Pilant Therapeutics, Inc. (USA)
Sagimet Biosciences (USA)
Gyre Therapeutics, Inc. (USA)
Akero Therapeutics, Inc. (USA)
CureVac SE (Deutschland)
Novo Nordisk A/S (Dänemark)
Ipsen Pharma (Frankreich)
AdAlta Limited (Australien)
Alentis Therapeutics AG (Schweiz)
Gilead Sciences, Inc. (USA)
AbbVie Inc. (USA)
Merck & Co., Inc. (USA)
Novartis AG (Schweiz)
Intercept Pharmaceuticals, Inc. (USA)

Neueste Entwicklungen auf dem Markt für Leberfibrosebehandlungen im Nahen Osten und Afrika

Im Juni 2024 präsentierte Gilead Sciences die neue Forschung auf dem Kongress der Middle East and Africaan Association for the Study of the Liver (EASL) 2024 in Mailand. Der Schwerpunkt lag auf Lebererkrankungen wie primärer biliärer Cholangitis (PBC), Hepatitis B (HBV), Hepatitis-Delta-Virus (HDV) und anderen. Zu den wichtigsten Präsentationen gehören Langzeitdaten der ASSURE-Studie zu Seladelpar bei PBC, Ergebnisse zu Tenofovir zur Leberkrebsprävention bei HBV sowie Erkenntnisse aus den Studien MYR204 und MYR301 zu Hepcludex bei HDV. Diese Forschung unterstreicht Gileads Engagement für die Weiterentwicklung von Behandlungsmöglichkeiten für Lebererkrankungen.
Im Oktober 2024 berichtete Intercept Pharmaceuticals, Inc. über seine laufenden Bemühungen, ethnische Unterschiede und Ungleichheiten in der Behandlung der primär biliären Cholangitis (PBC) zu untersuchen. Das Unternehmen befasst sich mit den unterschiedlichen Herausforderungen, die verschiedene Bevölkerungsgruppen bei der Diagnose, Behandlung und dem Management von PBC haben können. Durch die Untersuchung dieser Unterschiede möchte Intercept den Zugang zu Pflege und Behandlungsergebnissen für alle Patienten verbessern und so möglicherweise die Hürden für eine wirksame Behandlung von Lebererkrankungen, einschließlich Fibrose, abbauen.
Im November 2022 erteilte die US-amerikanische Food and Drug Administration (FDA) die Zulassung für Vemlidy (Tenofoviralafenamid) zur Behandlung einer chronischen Hepatitis-B-Virusinfektion (HBV) bei Kindern ab 12 Jahren mit kompensierter Lebererkrankung. Diese Zulassung erweitert den Anwendungsbereich von Vemlidy, das 2016 erstmals für Erwachsene mit chronischer HBV-Infektion zugelassen wurde. Die Zulassung basiert auf einer klinischen Phase-2-Studie, die die Wirksamkeit und Sicherheit von Vemlidy in dieser jüngeren Patientengruppe belegt.
Im September 2022 schloss Gilead Sciences die Übernahme von MiroBio ab, einem britischen Biotechnologieunternehmen, das sich auf die Wiederherstellung des Immunsystems durch Agonisten konzentriert, die auf immunhemmende Rezeptoren abzielen. Die Akquisition im Wert von rund 405 Millionen US-Dollar sichert Gilead die Forschungsplattform und das Portfolio an immunhemmenden Rezeptoragonisten von MiroBio. MiroBios führender Antikörper MB272 zielt auf Immunzellen ab, um entzündliche Immunreaktionen zu unterdrücken, und befindet sich derzeit in Phase 1 der klinischen Erprobung. Diese Übernahme verstärkt Gileads Bemühungen zur Behandlung chronischer immunvermittelter Erkrankungen.
Im März 2021 erweiterten Gilead Sciences und Novo Nordisk ihre Zusammenarbeit bei der Behandlung der nichtalkoholischen Steatohepatitis (NASH) mit dem Start einer klinischen Phase-2b-Studie. Die Studie untersucht die Sicherheit und Wirksamkeit von Semaglutid, einem GLP-1-Rezeptoragonisten von Novo Nordisk, in Kombination mit Gileads Cilofexor (einem FXR-Agonisten) und Firsocostat (einem ACC-Hemmer) bei Patienten mit Leberzirrhose aufgrund von NASH. Die Studie untersucht die Auswirkungen der Behandlungen auf Leberfibrose und NASH-Abheilung. Die Rekrutierung soll in der zweiten Jahreshälfte 2021 beginnen.

SKU-73831

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Klicken Sie auf das Bild, um es zu vergrößern

Interaktives Datenanalyse-Dashboard
Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
Zugriff für Research-Analysten für Anpassungen und Abfragen
Konkurrenzanalyse mit interaktivem Dashboard
Aktuelle Nachrichten, Updates und Trendanalyse
Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung

Demo anfordern

Inhaltsverzeichnis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 MULTIVARIATE MODELLING

2.6 TREATMENT TYPE LIFELINE CURVE

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTERS FIVE FORCES ANALYSIS

4.2.1 LIVER TRANSPLANTATION VOLUME AND THEIR COST FOR LIVER FIBROSIS BY COUNTRY

4.2.2 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES FOR LIVER FIBROSIS: VOLUME AND COST BY COUNTRY

4.2.3 PARTIAL HEPATECTOMY (LIVER RESECTION) COST BY COUNTRY

4.2.4 CELL-BASED THERAPY COST FOR LIVER FIBROSIS TREATMENT BY COUNTRY

4.3 EPIDEMIOLOGY

4.3.1 INCIDENCE OF ALL BY GENDER

4.3.2 TREATMENT RATE

4.3.3 TREATMENT RATE

4.3.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

4.3.5 PATIENT TREATMENT SUCCESS RATES

4.4 MARKETED DRUG ANALYSIS

4.5 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

4.5.1 PATIENT FLOW DIAGRAM

4.5.2 KEY PRICING STRATEGIES

4.5.3 KEY PATIENT ENROLLMENT STRATEGIES

5 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF LIVER DISEASES

6.1.2 RISING CONSUMPTION OF ALCOHOL

6.1.3 RISING LIVER TRANSPLANTATION RATES

6.1.4 GROWING INCIDENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) & NASH

6.2 RESTRAINTS

6.2.1 LIMITED AWARENESS OF LIVER DISEASES

6.2.2 REGULATORY CHALLENGES

6.3 OPPORTUNITIES

6.3.1 EMERGING TECHNOLOGIES AND ADVANCED TREATMENTS IN LIVER FIBROSIS MANAGEMENT

6.3.2 PROGRESS IN PIPELINE PRODUCTS FOR LIVER FIBROSIS TREATMENT

6.3.3 STRATEGIC MERGERS AND ACQUISITIONS AMONG THE KEY PLAYERS

6.4 CHALLENGES

6.4.1 LACK OF EFFECTIVE AND APPROVED ANTI-FIBROTIC DRUGS

6.4.2 HIGH COST OF TREATMENTS IN LIVER FIBROSIS CARE

7 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE

7.1 OVERVIEW

7.2 MEDICATION

7.2.1 ANTIVIRAL AGENTS

7.2.1.1 VELPATASVIR/SOFOSBUVIR

7.2.1.2 TENOFOVIR

7.2.1.3 LEDIPASVIR/SOFOSBUVIR

7.2.1.4 SOFOSBUVIR

7.2.1.5 ENTECAVIR

7.2.2 ANTIFIBROTIC AGENTS

7.2.2.1 OBETICHOLIC ACID

7.2.2.2 TGF-Β INHIBITORS

7.2.2.3 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) INHIBITORS

7.2.2.4 LYSYL OXIDASE-LIKE 2 (LOXL2) INHIBITORS

7.2.2.5 OTHERS

7.2.3 ANTI-INFLAMMATORY DRUGS

7.2.3.1 CORTICOSTEROIDS

7.2.3.1.1 PREDNISONE

7.2.3.1.2 DEXAMETHASONE

7.2.3.2 TUMOR NECROSIS FACTOR (TNF) INHIBITORS

7.2.3.2.1 INFLIXIMAB

7.2.3.2.2 ETANERCEPT

7.2.3.3 INTERLEUKIN (IL) INHIBITORS

7.2.3.3.1 IL-6 INHIBITORS (TOCILIZUMAB)

7.2.3.3.2 IL-1 INHIBITORS (ANAKINRA)

7.2.4 IMMUNOSUPPRESSANTS

7.2.4.1 MYCOPHENOLATE MOFETIL

7.2.4.2 TACROLIMUS

7.2.4.3 CYCLOSPORINE

7.2.5 MARKETED DRUGS

7.2.5.1 VELPATASVIR/SOFOSBUVIR

7.2.5.2 TENOFOVIR

7.2.5.3 LEDIPASVIR/SOFOSBUVIR

7.2.5.4 OBETICHOLIC ACID (OCA)

7.2.5.5 SOFOSBUVIR

7.2.5.6 PIRFENIDONE

7.2.5.7 OTHERS

7.2.6 PIPELINE DRUGS

7.2.7 BRANDED DRUGS

7.2.7.1 EPCLUSA

7.2.7.2 VIREAD AND VEMLIDY

7.2.7.3 OCALIVA

7.2.7.4 HARVONI

7.2.7.5 SOVALDI

7.2.7.6 BARACLUDE

7.2.7.7 ACTOS

7.2.7.8 OTHERS

7.2.8 GENERIC DRUGS

7.2.9 ORAL

7.2.10 PARENTERAL

7.2.11 OTHERS

7.3 SURGERY/THERAPY

7.3.1 LIVER TRANSPLANTATION

7.3.2 ORTHOTOPIC LIVER TRANSPLANT (OLT)

7.3.3 LIVING DONOR LIVER TRANSPLANT (LDLT)

7.3.4 SPLIT LIVER TRANSPLANTATION

7.3.5 DOMINO LIVER TRANSPLANT

7.3.6 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES

7.3.6.1 ENDOSCOPIC VARICEAL LIGATION (EVL)

7.3.6.2 TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS)

7.3.6.3 LIVER ABLATION PROCEDURES

7.3.6.3.1 RADIOFREQUENCY ABLATION (RFA)

7.3.6.3.2 MICROWAVE ABLATION (MWA)

7.3.7 PARTIAL HEPATECTOMY (LIVER RESECTION)

7.3.7.1 SEGMENTAL RESECTION

7.3.7.2 LOBECTOMY

7.3.7.3 WEDGE RESECTION

7.3.8 CELL-BASED THERAPY

7.3.8.1 STEM CELL THERAPY

7.3.8.1.1 MESENCHYMAL STEM CELLS (MSCS)

7.3.8.1.2 HEMATOPOIETIC STEM CELLS (HSCS)

7.3.8.2 GENE THERAPY

7.3.8.2.1 CRISPR-BASED LIVER REGENERATION

7.3.8.2.2 HEPATIC STELLATE CELL (HSC) INHIBITORS

7.3.8.2.3 SIRNA-BASED THERAPIES

7.3.8.2.4 HEPATOCYTE APOPTOSIS INHIBITORS

7.3.8.2.4.1 OXIDATIVE STRESS INHIBITORS

7.3.8.2.4.2 EMRICASAN

7.3.8.2.4.3 PENTOXIFYLLINE

7.3.8.2.4.4 LOSARTAN

7.3.8.2.4.5 METHYL FERULIC ACID

7.3.8.2.4.6 OTHERS

7.4 OTHERS

8 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY STAGES

8.1 OVERVIEW

8.2 F2

8.3 F1

8.4 F3

8.5 F4

9 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION

9.1 OVERVIEW

9.2 NON-ALCOHOLIC STEATOHEPATITIS (NASH)

9.3 HEPATITIS B & C-INDUCED FIBROSIS

9.3.1 CHRONIC HEPATITIS B VIRUS (HBV) FIBROSIS

9.3.2 CHRONIC HEPATITIS C VIRUS (HCV) FIBROSIS

9.4 ALCOHOLIC LIVER DISEASE (ALD)

9.5 AUTOIMMUNE LIVER DISEASES

9.5.1 AUTOIMMUNE HEPATITIS (AIH)

9.5.2 PRIMARY BILIARY CHOLANGITIS (PBC)

9.5.3 PRIMARY SCLEROSING CHOLANGITIS (PSC)

9.6 GENETIC DISORDERS

9.6.1 HEMOCHROMATOSIS

9.6.2 WILSON’S DISEASE

9.6.3 ALPHA-1 ANTITRYPSIN DEFICIENCY

9.7 OTHERS

10 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY GENDER

10.1 OVERVIEW

10.2 MALE

10.2.1 40-55 YEARS

10.2.2 ABOVE 55 YEARS

10.2.3 BELOW 40 YEARS

10.3 FEMALE

10.3.1 ABOVE 55 YEARS

10.3.2 40-55 YEARS

10.3.3 BELOW 40 YEARS

11 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.2.1 PUBLIC HOSPITALS

11.2.2 PRIVATE HOSPITALS

11.3 SPECIALTY CLINICS

11.3.1 HEPATOLOGY CLINICS

11.3.2 GASTROENTEROLOGY CLINICS

11.4 CLINICS

11.5 AMBULATORY AND RESEARCH CENTERS

11.6 OTHERS

12 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.2.1 RETAIL SALES

12.2.1.1 HOSPITAL PHARMACY

12.2.1.2 RETAIL PHARMACY

12.2.1.3 ONLINE PHARMACY

13 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY REGION

13.1 MIDDLE EAST AND AFRICA

13.1.1 SOUTH AFRICA

13.1.2 SAUDI ARABIA

13.1.3 U.A.E

13.1.4 EGYPT

13.1.5 ISRAEL

13.1.6 KUWAIT

13.1.7 QATAR

13.1.8 OMAN

13.1.9 REST OF MIDDLE EAST AND AFRICA

14 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: GLOBAL

15 SWOT ANALYSIS

16 COMPANY PROFILES

16.1 GILEAD SCIENCES, INC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENT/NEWS

16.2 ABBVIE, INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 MERCK & CO, INC.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENT

16.4 NOVARTIS AG

16.4.1 COMPANY SNAPSHOTS

16.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 PIPELINE PRODUCT PORTFOLIO

16.4.6 RECENT DEVELOPMENT

16.5 INTERCEPT PHARMACEUTICALS, INC.

16.5.1 COMPANY SNAPSHOTS

16.5.2 COMPANY SHARE ANALYSIS

16.5.3 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 PIPELINE PRODUCT PORTFOLIO

16.5.6 RECENT NEWS

16.6 ABBOTT

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 1.1.5 RECENT DEVELOPMENT

16.7 ALIGOS THERAPEUTICS

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 ALNICHE LIFE SCIENCES PVT. LTD.

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 ALENTIS THERAPEUTICS AG

16.9.1 COMPANY SNAPSHOT

16.9.2 PIPELINE PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENT

16.1 ADALTA LIMITED

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PIPELINE PRODUCT PORTFOLIO

16.10.4 RECENT NEWS

16.11 AKERO THERAPEUTICS, INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PIPELINE PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 BRISTOL-MYERS SQUIBB

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 CALLIDITAS THERAPEUTICS AB

16.13.1 COMPANY SNAPSHOT

16.13.2 PIPELINE PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENT

16.14 CUREVAC SE

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENT

16.15 CONATUSPHARMA

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT/NEWS

16.16 ENANTA PHARMACEUTICALS, INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 ECHOSENS

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENT/NEWS

16.18 F. HOFFMANN-LA ROCHE LTD

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 COMPANY SHARE ANALYSIS

16.18.4 PRODUCT PORTFOLIO

16.18.5 RECENT DEVELOPMENT

16.19 GALECTO BIOTECH

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PIPELINE PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT/NEWS

16.2 GALECTIN THERAPEUTICS, INC.

16.20.1 COMPANY SNAPSHOTS

16.20.2 REVENUE ANALYSIS AND SEGMENTAL ANALYSIS

16.20.3 PIPELINE PRODUCT PORTFOLIO

16.20.4 RECENT DEVELOPMENT

16.21 GYRE THERAPEUTICS, INC.

16.21.1 COMPANY SNAPSHOT

16.21.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.21.3 PRODUCT PORTFOLIO

16.21.4 RECENT DEVELOPMENT/NEWS

16.22 GENFIT SA

16.22.1 COMPANY SNAPSHOTS

16.22.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.22.3 PIPELINE PRODUCT PORTFOLIO

16.22.4 RECENT DEVELOPMENT

16.23 HEPION PHARMACEUTICALS

16.23.1 COMPANY SNAPSHOT

16.23.2 REVENUE ANALYSIS

16.23.3 PIPELINE PORTFOLIO

16.23.4 RECENT DEVELOPMENT

16.24 IPSEN PHARMA

16.24.1 COMPANY SNAPSHOT

16.24.2 REVENUE ANALYSIS

16.24.3 PIPELINE PRODUCT PORTFOLIO

16.24.4 RECENT NEWS/DEVELOPMENTS

16.25 LA RENON HEALTHCARE PVT. LTD.

16.25.1 COMPANY SNAPSHOT

16.25.2 PRODUCT PORTFOLIO

16.25.3 RECENT DEVELOPMENT

16.26 MADRIGAL PHARMACEUTICALS

16.26.1 COMPANY SNAPSHOTS

16.26.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.26.3 PRODUCT PORTFOLIO

16.26.4 RECENT DEVELOPMENT

16.27 NOVO NORDISK A/S

16.27.1 COMPANY SNAPSHOT

16.27.2 REVENUE ANALYSIS

16.27.3 PIPELINE PRODUCT PORTFOLIO

16.27.4 RECENT DEVELOPMENT

16.28 NOVOMEDIX

16.28.1 COMPANY SNAPSHOT

16.28.2 PIPELINE PRODUCT PORTFOLIO

16.28.3 RECENT DEVELOPMENT

16.29 PILANT THERAPEUTICS, INC.

16.29.1 COMPANY SNAPSHOT

16.29.2 REVENUE ANALYSIS

16.29.3 PIPELINE PRODUCT PORTFOLIO

16.29.4 RECENT NEWS

16.3 PFIZER INC.

16.30.1 COMPANY SNAPSHOT

16.30.2 REVENUE ANALYSIS

16.30.3 PIPELINE PRODUCT PORTFOLIO

16.30.4 RECENT DEVELOPMENT/NEWS

16.31 SAGIMET BIOSCIENCES

16.31.1 COMPANY SNAPSHOTS

16.31.2 REVENUE ANALYSIS

16.31.3 1.1.4 PRODUCT PORTFOLIO

16.31.4 RECENT DEVELOPMENT/NEWS

16.32 TAKEDA PHARMACEUTICAL COMPANY LIMITED

16.32.1 COMPANY SNAPSHOT

16.32.2 REVENUE ANALYSIS

16.32.3 PIPELINE PRODUCT PORTFOLIO

16.32.4 PRODUCT PORTFOLIO

16.32.5 RECENT DEVELOPMENT

16.33 TVARDI THERAPEUTICS

16.33.1 COMPANY SNAPSHOT

16.33.2 PIPELINE PRODUCT PORTFOLIO

16.33.3 RECENT DEVELOPMENT/NEWS

16.34 VERTEX PHARMACEUTICALS INCORPORATED

16.34.1 COMPANY SNAPSHOT

16.34.2 REVENUE ANALYSIS

16.34.3 PRODUCT PORTFOLIO

16.34.4 RECENT DEVELOPMENT

16.35 VIKING THERAPEUTICS

16.35.1 COMPANY SNAPSHOT

16.35.2 REVENUE ANALYSIS

16.35.3 PIPELINE PRODUCT PORTFOLIO

16.35.4 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

Tabellenverzeichnis

TABLE 1 MIDDLE EAST AND AFRICA INCIDENCE OF CIRRHOSIS BY GENDER (2019)

TABLE 2 TREATMENT ADHERENCE LEVELS IN LIVER DISEASE PATIENTS

TABLE 3 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 4 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 5 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 6 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 7 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 8 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 9 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 10 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 11 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 12 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 13 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 14 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 15 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 16 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 17 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 18 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 19 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 20 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 22 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 23 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 24 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 25 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 26 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 27 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 28 MIDDLE EAST AND AFRICA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 29 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 30 MIDDLE EAST AND AFRICA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 31 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 32 MIDDLE EAST AND AFRICA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 33 MIDDLE EAST AND AFRICA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 34 MIDDLE EAST AND AFRICA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 35 MIDDLE EAST AND AFRICA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 36 MIDDLE EAST AND AFRICA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 37 MIDDLE EAST AND AFRICA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 38 MIDDLE EAST AND AFRICA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 39 MIDDLE EAST AND AFRICA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 40 MIDDLE EAST AND AFRICA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 41 MIDDLE EAST AND AFRICA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 42 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 43 MIDDLE EAST AND AFRICA F2 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 44 MIDDLE EAST AND AFRICA F1 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 45 MIDDLE EAST AND AFRICA F3 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 46 MIDDLE EAST AND AFRICA F4 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 47 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 48 MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 49 MIDDLE EAST AND AFRICA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 50 MIDDLE EAST AND AFRICA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 51 MIDDLE EAST AND AFRICA ALCOHOLIC LIVER DISEASE (ALD) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 52 MIDDLE EAST AND AFRICA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 53 MIDDLE EAST AND AFRICA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 54 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 55 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 56 MIDDLE EAST AND AFRICA OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 57 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 58 MIDDLE EAST AND AFRICA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 59 MIDDLE EAST AND AFRICA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 60 MIDDLE EAST AND AFRICA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 61 MIDDLE EAST AND AFRICA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 62 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 63 MIDDLE EAST AND AFRICA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 64 MIDDLE EAST AND AFRICA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 65 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 66 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 MIDDLE EAST AND AFRICA CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 68 MIDDLE EAST AND AFRICA AMBULATORY AND RESEARCH CENTERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 69 MIDDLE EAST AND AFRICA OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 70 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 71 MIDDLE EAST AND AFRICA DIRECT TENDER IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 72 MIDDLE EAST AND AFRICA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 73 MIDDLE EAST AND AFRICA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 74 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 75 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 76 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 78 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 79 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 80 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 81 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 83 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 84 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 85 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 86 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 87 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 88 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 89 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 90 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 91 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 92 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 93 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 94 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 95 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 96 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 97 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 98 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 99 MIDDLE EAST AND AFRICA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 100 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 101 MIDDLE EAST AND AFRICA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 102 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 103 MIDDLE EAST AND AFRICA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 104 MIDDLE EAST AND AFRICA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 105 MIDDLE EAST AND AFRICA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 106 MIDDLE EAST AND AFRICA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 107 MIDDLE EAST AND AFRICA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 108 MIDDLE EAST AND AFRICA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 MIDDLE EAST AND AFRICA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 110 MIDDLE EAST AND AFRICA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 MIDDLE EAST AND AFRICA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 112 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 113 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 114 MIDDLE EAST AND AFRICA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 115 MIDDLE EAST AND AFRICA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 116 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 117 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 118 MIDDLE EAST AND AFRICA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 119 MIDDLE EAST AND AFRICA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 120 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 121 MIDDLE EAST AND AFRICA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 122 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 123 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 124 MIDDLE EAST AND AFRICA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 SOUTH AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127 SOUTH AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 128 SOUTH AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 129 SOUTH AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 130 SOUTH AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 131 SOUTH AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 SOUTH AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 133 SOUTH AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 134 SOUTH AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 135 SOUTH AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 136 SOUTH AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 SOUTH AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 138 SOUTH AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 139 SOUTH AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 SOUTH AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 141 SOUTH AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 142 SOUTH AFRICA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 143 SOUTH AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 144 SOUTH AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 145 SOUTH AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 146 SOUTH AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 147 SOUTH AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 148 SOUTH AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 149 SOUTH AFRICA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 SOUTH AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 151 SOUTH AFRICA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 152 SOUTH AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 153 SOUTH AFRICA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 SOUTH AFRICA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 SOUTH AFRICA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 156 SOUTH AFRICA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 157 SOUTH AFRICA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 158 SOUTH AFRICA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 159 SOUTH AFRICA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 160 SOUTH AFRICA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 SOUTH AFRICA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 162 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 163 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 164 SOUTH AFRICA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 SOUTH AFRICA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 166 SOUTH AFRICA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 167 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 168 SOUTH AFRICA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 SOUTH AFRICA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 171 SOUTH AFRICA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 172 SOUTH AFRICA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 173 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 174 SOUTH AFRICA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 176 SAUDI ARABIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 177 SAUDI ARABIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 178 SAUDI ARABIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 SAUDI ARABIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 180 SAUDI ARABIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 181 SAUDI ARABIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 SAUDI ARABIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 183 SAUDI ARABIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 184 SAUDI ARABIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 185 SAUDI ARABIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 186 SAUDI ARABIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 187 SAUDI ARABIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 188 SAUDI ARABIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 189 SAUDI ARABIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 SAUDI ARABIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 191 SAUDI ARABIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 192 SAUDI ARABIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 193 SAUDI ARABIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 194 SAUDI ARABIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 195 SAUDI ARABIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 SAUDI ARABIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 197 SAUDI ARABIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 198 SAUDI ARABIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 199 SAUDI ARABIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 200 SAUDI ARABIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 201 SAUDI ARABIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202 SAUDI ARABIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 203 SAUDI ARABIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 204 SAUDI ARABIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 SAUDI ARABIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 206 SAUDI ARABIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 207 SAUDI ARABIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 SAUDI ARABIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 209 SAUDI ARABIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 210 SAUDI ARABIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 SAUDI ARABIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 213 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 214 SAUDI ARABIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 SAUDI ARABIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 216 SAUDI ARABIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 218 SAUDI ARABIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 SAUDI ARABIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 221 SAUDI ARABIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 222 SAUDI ARABIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 224 SAUDI ARABIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 U.A.E MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 U.A.E MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 228 U.A.E ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 229 U.A.E ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 230 U.A.E ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 231 U.A.E ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 U.A.E ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 233 U.A.E ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 234 U.A.E ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 235 U.A.E ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 236 U.A.E CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 237 U.A.E CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 238 U.A.E CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 239 U.A.E TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 240 U.A.E TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 241 U.A.E TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 242 U.A.E INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 243 U.A.E INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 244 U.A.E INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 245 U.A.E IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 U.A.E IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 247 U.A.E IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 248 U.A.E MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 249 U.A.E MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 U.A.E MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 251 U.A.E BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 U.A.E MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 253 U.A.E SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 U.A.E LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 U.A.E ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 U.A.E LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 257 U.A.E PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 258 U.A.E CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 259 U.A.E STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 260 U.A.E GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 261 U.A.E HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 262 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 263 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 264 U.A.E HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 265 U.A.E AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 U.A.E GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 267 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 268 U.A.E MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 U.A.E FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 271 U.A.E HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 272 U.A.E SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 274 U.A.E RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 276 EGYPT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 EGYPT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 278 EGYPT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 EGYPT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 280 EGYPT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 281 EGYPT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 282 EGYPT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 283 EGYPT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 284 EGYPT ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 EGYPT ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 286 EGYPT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 287 EGYPT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 288 EGYPT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 289 EGYPT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 290 EGYPT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 291 EGYPT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 292 EGYPT INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 293 EGYPT INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 294 EGYPT INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 295 EGYPT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 296 EGYPT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 297 EGYPT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 298 EGYPT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 299 EGYPT MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 EGYPT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 301 EGYPT BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 EGYPT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 303 EGYPT SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 304 EGYPT LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 EGYPT ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 EGYPT LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 307 EGYPT PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 308 EGYPT CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 309 EGYPT STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 310 EGYPT GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 311 EGYPT HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 312 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 313 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 314 EGYPT HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 315 EGYPT AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 316 EGYPT GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 317 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 318 EGYPT MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 319 EGYPT FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 321 EGYPT HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 322 EGYPT SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 323 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 324 EGYPT RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 325 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 326 ISRAEL MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 ISRAEL MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 328 ISRAEL ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 ISRAEL ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 330 ISRAEL ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 331 ISRAEL ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 332 ISRAEL ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 333 ISRAEL ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 334 ISRAEL ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 335 ISRAEL ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 336 ISRAEL CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 ISRAEL CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 338 ISRAEL CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 339 ISRAEL TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 340 ISRAEL TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 341 ISRAEL TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 342 ISRAEL INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 ISRAEL INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 344 ISRAEL INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 345 ISRAEL IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 346 ISRAEL IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 347 ISRAEL IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 348 ISRAEL MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 349 ISRAEL MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 ISRAEL MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 ISRAEL BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 352 ISRAEL MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 353 ISRAEL SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 ISRAEL LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 355 ISRAEL ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 ISRAEL LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 ISRAEL PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 ISRAEL CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 359 ISRAEL STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 ISRAEL GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 361 ISRAEL HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 363 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 364 ISRAEL HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 365 ISRAEL AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 366 ISRAEL GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 367 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 368 ISRAEL MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 369 ISRAEL FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 371 ISRAEL HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 ISRAEL SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 373 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 374 ISRAEL RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 375 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 376 KUWAIT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 377 KUWAIT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 378 KUWAIT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 379 KUWAIT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 380 KUWAIT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 381 KUWAIT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 382 KUWAIT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 383 KUWAIT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 384 KUWAIT ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 385 KUWAIT ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 386 KUWAIT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 387 KUWAIT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 388 KUWAIT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 389 KUWAIT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 390 KUWAIT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 391 KUWAIT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 392 KUWAIT INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 393 KUWAIT INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 394 KUWAIT INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 395 KUWAIT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 396 KUWAIT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 397 KUWAIT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 398 KUWAIT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 399 KUWAIT MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 400 KUWAIT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 KUWAIT BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 402 KUWAIT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 403 KUWAIT SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 404 KUWAIT LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 405 KUWAIT ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 406 KUWAIT LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 407 KUWAIT PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 KUWAIT CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 409 KUWAIT STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 410 KUWAIT GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 411 KUWAIT HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 412 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 413 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 414 KUWAIT HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 KUWAIT AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 KUWAIT GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 417 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 418 KUWAIT MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 419 KUWAIT FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 420 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 421 KUWAIT HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 422 KUWAIT SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 423 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 424 KUWAIT RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 425 QATAR LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 426 QATAR MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 427 QATAR MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 428 QATAR ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 429 QATAR ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 430 QATAR ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 431 QATAR ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 432 QATAR ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 433 QATAR ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 434 QATAR ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 435 QATAR ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 436 QATAR CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 437 QATAR CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 438 QATAR CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 439 QATAR TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 440 QATAR TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 441 QATAR TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 442 QATAR INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 443 QATAR INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 444 QATAR INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 445 QATAR IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 446 QATAR IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 447 QATAR IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 448 QATAR MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 449 QATAR MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 450 QATAR MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 451 QATAR BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 452 QATAR MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 453 QATAR SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 454 QATAR LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 455 QATAR ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 456 QATAR LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 457 QATAR PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 458 QATAR CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 459 QATAR STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 460 QATAR GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 461 QATAR HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 462 QATAR LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 463 QATAR LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 464 QATAR HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 465 QATAR AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 466 QATAR GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 467 QATAR LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 468 QATAR MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 469 QATAR FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 470 QATAR LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 471 QATAR HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 472 QATAR SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 473 QATAR LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 474 QATAR RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 475 OMAN LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 476 OMAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 477 OMAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 478 OMAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 479 OMAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 480 OMAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 481 OMAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 482 OMAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 483 OMAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 484 OMAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 485 OMAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 486 OMAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 487 OMAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 488 OMAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 489 OMAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 490 OMAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 491 OMAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 492 OMAN INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 493 OMAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 494 OMAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 495 OMAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 496 OMAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 497 OMAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 498 OMAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 499 OMAN MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 500 OMAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 501 OMAN BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 502 OMAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 503 OMAN SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 504 OMAN LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 505 OMAN ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 506 OMAN LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 507 OMAN PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 508 OMAN CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 509 OMAN STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 510 OMAN GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 511 OMAN HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 512 OMAN LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 513 OMAN LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 514 OMAN HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 515 OMAN AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 516 OMAN GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 517 OMAN LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 518 OMAN MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 519 OMAN FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 520 OMAN LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 521 OMAN HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 522 OMAN SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 523 OMAN LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 524 OMAN RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 525 REST OF MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

Abbildungsverzeichnis

FIGURE 1 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE OF LIVER DISEASES IS EXPECTED TO DRIVE THE GROWTH OF MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET FROM 2025 TO 2032

FIGURE 12 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET IN 2025-2032

FIGURE 13 TWO SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE

FIGURE 14 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: EXECUTIVE SUMMARY

FIGURE 15 STRATEGIC DECISIONS

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET

FIGURE 17 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2024

FIGURE 18 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)

FIGURE 19 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)

FIGURE 20 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 21 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2024

FIGURE 22 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2025-2032 (USD THOUSAND)

FIGURE 23 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY STAGES, CAGR (2025-2032)

FIGURE 24 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY STAGES, LIFELINE CURVE

FIGURE 25 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2024

FIGURE 26 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2025-2032 (USD THOUSAND)

FIGURE 27 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, CAGR (2025-2032)

FIGURE 28 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 29 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2024

FIGURE 30 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)

FIGURE 31 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY GENDER, CAGR (2025-2032)

FIGURE 32 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 33 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2024

FIGURE 34 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)

FIGURE 35 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY END USER, CAGR (2025-2032)

FIGURE 36 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 37 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2024

FIGURE 38 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)

FIGURE 39 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)

FIGURE 40 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 41 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: SNAPSHOT (2024)

FIGURE 42 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: COMPANY SHARE 2024 (%)

Detaillierte Informationen anzeigen

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

What is the current market size of the Middle East and Africa liver fibrosis treatment market?

The Middle East and Africa liver fibrosis treatment market size was valued at USD 935.44 million in 2024.

What is the expected growth rate of Middle East and Africa liver fibrosis treatment market ?

The Middle East and Africa liver fibrosis treatment market is to grow at a CAGR of 12.3 % during the forecast period of 2025 to 2032.

What are the primary segments covered in the Middle East and Africa liver fibrosis treatment market ?

The Middle East and Africa liver fibrosis treatment market is segmented into five notable segments based on treatment type, stages, indication, end user, and distribution channel. On the basis of treatment type, the market is segmented into medication and surgery/therapy. on the basis of stages, the market is segmented into F2, F1, F3, and F4, on the basis of indication, the market is segmented into non-alcoholic steatohepatitis (Nash), hepatitis B and C-induced fibrosis, alcoholic liver disease (ALD), autoimmune liver diseases, genetic disorders, and others. on the basis of gender, the market is segmented into male and female. on the basis of end user, the market is segmented into hospitals, specialty clinics, clinics, ambulatory and research centers, and others. on the basis of distribution channel, the market is segmented into direct tender and retail sales.

Who are major players in Middle East and Africa liver fibrosis treatment ?

Companies such as Gilead Sciences, Inc. (U.S.),AbbVie Inc. (U.S.),Merck and Co., Inc. (U.S.),Novartis AG (Switzerland), Intercept Pharmaceuticals, Inc. (U.S.)are the major companies in the Middle East and Africa liver fibrosis treatment.

What are the recent product launches by major companies in the Middle East and Africa liver fibrosis treatment ?

In October 2024, Intercept Pharmaceuticals, Inc discussed their ongoing efforts to explore racial differences and disparities in Primary Biliary Cholangitis (PBC) care. The company is addressing how various populations may face different challenges in the diagnosis, treatment, and management of PBC. By exploring these disparities, Intercept aims to improve access to care and treatment outcomes for all patients, potentially reducing barriers to effective treatment of liver diseases, including fibrosis.

Which countries data is covered in the Middle East and Africa liver fibrosis treatment ?

The countries covered in the Middle East and Africa liver fibrosis treatment are Saudi Arabia, U.A.E., South Africa, Egypt, Kuwait, Israel, and rest of Middle East and Africa.

What are the key trends in the Middle East and Africa liver fibrosis treatment ?

Increasing prevalence of liver diseases , is emerging as a pivotal trend driving the Middle East and Africa liver fibrosis treatment .

What are the factors driving the Middle East and Africa liver fibrosis treatment growth?

The major factors driving the growth of Middle East and Africa liver fibrosis treatment are rising consumption of alcohol, rising liver transplantation rates, and growing incidence of non-alcoholic fatty liver disease (NAFLD) and NASH.

What are the major challenges in the Middle East and Africa liver fibrosis treatment ?

The primary challenges include long-term follow-ups associated with liver fibrosis treatment, high costs, limited curative options, and patient adherence issues.

Which is the dominating segment in the Middle East and Africa liver fibrosis treatment ?

The treatment type segment is expected to dominate the Middle East and Africa liver fibrosis treatment market in 2025 due to increasing demand for effective therapies, ongoing clinical trials, and rising approvals of novel drugs.

Which country is expected to dominate in the Middle East and Africa liver fibrosis treatment ?

Saudi Arabia leads the liver fibrosis treatment market in the Middle East & Africa, driven by a high prevalence of liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and hepatitis C, alongside a strong focus on healthcare modernization under the Vision 2030 initiative.

Which country is expected to witness the highest CAGR in Middle East and Africa liver fibrosis treatment ?

Saudi Arabia is expected to witness the highest CAGR in the Middle East and Africa liver fibrosis treatment market, driven by rising disease prevalence, healthcare reforms, and increased R&D.

Marktgröße, Marktanteil und Trendanalysebericht zur Behandlung von Leberfibrose im Nahen Osten und Afrika – Branchenüberblick und Prognose bis 2032

Umgehen Sie die Zollherausforderungen mit agiler Supply-Chain-Beratung

Middle East And Africa Liver Fibrosis Treatment Market

CAGR : 12.30 %

Marktgröße für die Behandlung von Leberfibrose im Nahen Osten und Afrika

Marktanalyse für die Behandlung von Leberfibrose im Nahen Osten und Afrika

Marktumfang der Leberfibrosebehandlung im Nahen Osten und in Afrika

Marktanteil der Leberfibrosebehandlung im Nahen Osten und Afrika

Neueste Entwicklungen auf dem Markt für Leberfibrosebehandlungen im Nahen Osten und Afrika

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Inhaltsverzeichnis

Tabellenverzeichnis

Abbildungsverzeichnis

Forschungsmethodik

Anpassung möglich

Häufig gestellte Fragen

Berichte

Markteinblicke

Unterstützung

Lösungen

Marktgröße, Marktanteil und Trendanalysebericht zur Behandlung von Leberfibrose im Nahen Osten und Afrika – Branchenüberblick und Prognose bis 2032

Umgehen Sie die Zollherausforderungen mit agiler Supply-Chain-Beratung

Middle East And Africa Liver Fibrosis Treatment Market

CAGR : 12.30 %

Marktgröße für die Behandlung von Leberfibrose im Nahen Osten und Afrika

Marktanalyse für die Behandlung von Leberfibrose im Nahen Osten und Afrika

Marktumfang der Leberfibrosebehandlung im Nahen Osten und in Afrika

Marktanteil der Leberfibrosebehandlung im Nahen Osten und Afrika

Neueste Entwicklungen auf dem Markt für Leberfibrosebehandlungen im Nahen Osten und Afrika

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Inhaltsverzeichnis

Tabellenverzeichnis

Abbildungsverzeichnis

Forschungsmethodik

Anpassung möglich

Häufig gestellte Fragen

Verwandte Seiten durchsuchen